

United Therapeutics Corp. (UTHR)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001082554

United Therapeutics Corp. UTHR; healthcare	
Grade	A ▼ A B C D E strongest fifth of 371 graded peers percentile 6.5; sampling error 2.5 points; lower is stronger
Rank	25 of 371
Profitability	C percentile 47.9
Solvency	A percentile 12.0
Growth and financing	B percentile 33.6
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$7.9B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: fortress balance sheet
Inputs computable	11 of 14
Graded from	filings received through Feb 25, 2026 226 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026
Last close	\$532.45 2026-10-08; market equity \$22.8B
Price used in grade	None




A, the bull

strongest fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan


split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: A/B from Mar 21, 2022, A from Mar 21, 2023, A/B from Feb 21, 2024, A from Sep

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 25, 2026

Founded by our Chairperson and Chief Executive Officer, Martine Rothblatt, to find a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension (PAH), United Therapeutics advances therapies for people living with serious diseases with unmet medical needs. Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies. As a public benefit corporation (PBC), we aim to deliver meaningful impacts

for our patients, our people, our shareholders, and other stakeholders.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 47.9						
Gross profitability		35.5%	32.2%	38.3	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(3.0%)	(6.6%)	71.6	811	2025-12-31
Gross margin stability, five years		1.9 pts	2.8 pts	33.9	243	2025-12-31
Solvency, sleeve percentile 12.0						
Twelve-month failure probability		0.02%	0.07%	4.9	248	2026-06-30
Altman Z double-prime		16.93	(0.31)	3.4	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		6.60x	2.96x	27.6	839	2025-12-31
Growth and financing, sleeve percentile 33.6						
Revenue growth, three-year compound		18.0%	10.0%	34.3	415	2025-12-31
Free cash flow growth, three-year compound		16.2%	10.9%	46.3	96	2025-12-31
Reinvestment rate		37.9%	37.1%	48.5	104	2025-12-31
Asset growth, three years		9.2%	2.1%	32.4	704	2025-12-31
Net share issuance, one year		(2.4%)	2.5%	6.5	634	2026-02-18

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
20	Biomarin Pharmaceutical Inc. (BMRN)	5.1	A	
21	Neurocrine Biosciences Inc. (NBIX)	5.4	A	
22	Crispr Therapeutics AG (CRSP)	5.7	A	
23	SBC Medical Group Holdings Inc. (SBC)	6.1	A	fortress
				balance sheet
24	SBC Medical Group Holdings Inc. (SBCWW)	6.1	A	fortress
				balance sheet
25	United Therapeutics Corp. (UTHR) <	6.5	A	

26	AtriCure, Inc. (ATRC)	6.8	A
27	Intuitive Surgical Inc. (ISRG)	7.0	A
28	iRhythm Holdings, Inc. (IRTC)	7.3	A fortress
			balance sheet
29	Globus Medical Inc. (GMED)	7.6	A
30	Hims & Hers Health, Inc. (HIMS)	7.8	A

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	21.7%	8.0%	60
Distance from 52-week high	(10.7%)	(31.4%)	82
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	4.6%	(1.0%)	79
Book value to price	0.28	0.28	50
Sales to price	0.14	0.31	33
Composite equity issuance, five years	(3.8%)	20.3%	22
Relative strength against the sector, log excess return	(0.02)	(0.14)	60

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$1.8B
Operating cash flow, four quarters	\$1.7B
Months of runway	not finite
Days since last periodic filing	65 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	\$247.7M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$2.8B	2025-12-31	2026-02-25	10-K	0001082554-26-000006
2	assets	us-gaap:Assets	\$7.9B	2025-12-31	2026-02-25	10-K	0001082554-26-000006
3	net income	us-gaap:NetIncomeLoss	\$1.3B	2025-12-31	2026-02-25	10-K	0001082554-26-000006
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.6B	2025-12-31	2026-02-25	10-K	0001082554-26-000006
5	assets	us-gaap:Assets	\$7.4B	2024-12-31	2026-02-25	10-K	0001082554-26-000006
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$3.2B	2025-12-31	2026-02-25	10-K	0001082554-26-000006
7	gross profit	us-gaap:GrossProfit	\$2.6B	2024-12-31	2026-02-25	10-K	0001082554-26-000006
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$2.9B	2024-12-31	2026-02-25	10-K	0001082554-26-000006
9	gross profit	us-gaap:GrossProfit	\$2.1B	2023-12-31	2026-02-25	10-K	0001082554-26-000006
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$2.3B	2023-12-31	2026-02-25	10-K	0001082554-26-000006
11	gross profit	us-gaap:GrossProfit	\$1.8B	2022-12-31	2025-02-26	10-K	0001082554-25-000005
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.9B	2022-12-31	2025-02-26	10-K	0001082554-25-000005
13	gross profit	us-gaap:GrossProfit	\$1.6B	2021-12-31	2024-02-21	10-K	0001082554-24-000005
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.7B	2021-12-31	2024-02-21	10-K	0001082554-24-000005
15	current assets	us-gaap:AssetsCurrent	\$3.7B	2025-12-31	2026-02-25	10-K	0001082554-26-000006
16	current liabilities	us-gaap:LiabilitiesCurrent	\$560.6M	2025-12-31	2026-02-25	10-K	0001082554-26-000006

17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$8.6B	2025-12-31	2026-02-25	10-K	0001082554-26-000006
18	operating income	us-gaap:OperatingIncomeLoss	\$1.5B	2025-12-31	2026-02-25	10-K	0001082554-26-000006
19	book equity	us-gaap:StockholdersEquity	\$7.1B	2025-12-31	2026-02-25	10-K	0001082554-26-000006
20	liabilities	us-gaap:Liabilities	\$783.8M	2025-12-31	2026-02-25	10-K	0001082554-26-000006
21	operating income	us-gaap:OperatingIncomeLoss	\$1.2B	2023-12-31	2026-02-25	10-K	0001082554-26-000006
22	interest expense	us-gaap:InterestExpense	\$59.3M	2023-12-31	2024-02-21	10-K	0001082554-24-000005
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$520.5M	2025-12-31	2026-02-25	10-K	0001082554-26-000006
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.3B	2024-12-31	2026-02-25	10-K	0001082554-26-000006
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$246.5M	2024-12-31	2026-02-25	10-K	0001082554-26-000006
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$978.0M	2023-12-31	2026-02-25	10-K	0001082554-26-000006
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$230.4M	2023-12-31	2026-02-25	10-K	0001082554-26-000006
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$802.5M	2022-12-31	2025-02-26	10-K	0001082554-25-000005
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$138.8M	2022-12-31	2025-02-26	10-K	0001082554-25-000005
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$85.6M	2025-12-31	2026-02-25	10-K	0001082554-26-000006
31	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$1.7B	2025-12-31	2026-02-25	10-K	0001082554-26-000006
32	income tax	us-gaap:IncomeTaxExpenseBenefit	\$379.2M	2025-12-31	2026-02-25	10-K	0001082554-26-000006
33	current assets	us-gaap:AssetsCurrent	\$3.9B	2024-12-31	2026-02-25	10-K	0001082554-26-000006
34	current liabilities	us-gaap:LiabilitiesCurrent	\$738.1M	2024-12-31	2026-02-25	10-K	0001082554-26-000006
35	assets	us-gaap:Assets	\$7.2B	2023-12-31	2025-02-26	10-K	0001082554-25-000005
36	assets	us-gaap:Assets	\$6.0B	2022-12-31	2024-02-21	10-K	0001082554-24-000005
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	43,827,686	2026-02-18	2026-02-25	10-K	0001082554-26-000006
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	44,912,177	2025-02-19	2025-02-26	10-K	0001082554-25-000005